(a) Relative mRNA levels of histone acetyltransferases (P300, CREBBP) in [CD4.sup.+] T lymphocytes from patients with LADA (n = 28) and controls (n = 28), as measured by real-time PCR.
(a) Relative mRNA levels of histone acetyltransferase (CREBBP) in [CD4.sup.+] T lymphocytes from patients with LADA, LADA patients with complications (LADAc, n = 17) versus LADA patients without complications (LADAnc, n = 11), * P < 0.05.
Proteins in the gel were transferred onto polyvinylidene difluoride (PVDF) membrane (pore size, 0.45 [micro]m; Millipore, Bedford, MA, USA) by electro-blotting (Matsuda et al., 2004) and then treated with rabbit polyclonal antibody against the DNA-binding domain of mouse JUN (D, 0.04 [micro]g/ml; Santa Cruz Biotechnology, Santa Cruz, CA, USA), the C-terminus of human ETS2 (C-20, 0.04 [micro]g/ml; Santa Cruz Biotechnology), the N-terminus of human CDX2 (ab22586, 0.04 [micro]g/ml; Abcam, Cambridge, UK), the N-terminus of human OCT4 (N-19, 0.04 [micro]g/ml; Santa Cruz Biotechnology), or the C-terminus of human CREBBP
(C-1, 0.04 [micro]g/ml; Santa Cruz Biotechnology).
(13, 14) A South Korean study by Jung et al (14) reported that TNFAIP3 was the most frequently mutated gene in ocular MZL followed by TBL1XR1 and CREBBP
, and MYD88 mutation was identified in only 4% of patients.
elegans) (EGLN3); E1A binding protein p300 (EP300); and CREB binding protein (CREBBP
), whereas miR-200b, miR-200c, and miR-429 target VHL; transcription elongation factor B (SIII), polypeptide 1 (15 kDa, elongin C) (TCEB1); EGLN1/3; EP300; and CREBBP
B01 PTEN loss; 0 RB1 splice site 607+2T>A (19) TP53 Y220S (26) CREBBP
K1086* (18) B02 PTEN R14fs*10 (24) TP53 VI 73fs*7 (33) TNERSEl 4 loss; 0 B03 PIK3CA H1047R (4) TP53 K320* (5) B04 MCL1 amplification; 7 ARID1A R1722* (4) NFKBIA amplification; 6 PTPN11 S502L (2) B05 PIK3R1 Y580fs*19 (42) CCND2 amplification; 24 CDKN2A loss; 0 FCF23 amplification; 24 B06 FANCA CI 410fs*6 (12) MYC amplification; 8 B07 CDK4 amplification;!